Sun Pharma Still a Good Buy: Sarabjit Kour Nangra
Sarabjit Kour Nangra of Angel Broking said the brokerage has been vouching Sun Pharma as a buy since the stock corrected to 720-730 levels as the market had factored in issues related to the Halol unit. Our view has not changed, she added.
